Skip to main content

Posts

Showing posts from October 30, 2025

#Asymptomatic #Human #Infections With Avian #Influenza #H5N1 Virus Confirmed by Molecular and Serologic Testing - A Scoping Review

  Key Points -- Question :  Have asymptomatic infections with highly pathogenic avian influenza A(H5N1) virus been reported in humans? -- Findings:  This scoping review of published reports through August 25, 2025, identified 10 reports of 18 cases of asymptomatic infection with A( H5N1 ) virus, including 2 cases with molecular and serologic confirmation and 16 cases with molecular confirmation alone. Symptom ascertainment methods varied among reported cases. -- Meaning:   Asymptomatic human avian influenza A(H5N1) virus infections have been infrequently reported , with most lacking serologic confirmation; prospective surveillance studies with serial respiratory and serum sampling and detailed symptom monitoring for persons with high-risk exposures could provide data to inform future public health responses. Abstract Importance    Since 1997, more than 1000 infections with highly pathogenic avian influenza A(H5N1) virus among humans have been reported globa...

Updated #Evidence for #Covid19, #RSV, and #Influenza #Vaccines for 2025–2026

  Abstract Background Changes in the vaccine advisory process in the United States have disrupted immunization guidance , which reinforces the need for independent evidence review to inform decisions regarding immunization for respiratory viruses during the 2025–2026 season. Methods We conducted a systematic review of U.S.-licensed immunizations against coronavirus disease 2019 (Covid-19), respiratory syncytial virus (RSV), and influenza . We searched databases on PubMed/MEDLINE, Embase, and Web of Science for updates of the most recent review by the Advisory Committee on Immunization Practices (ACIP) Evidence-to-Recommendations for each disease, which was performed during the 2023–2024 period. Outcomes included vaccine efficacy and effectiveness against hospitalization, other clinical end points, and safety. Results Of 17,263 identified references, 511 studies met the inclusion criteria. Covid-19 mRNA vaccines against the XBB.1.5 subvariant had pooled vaccine effectiveness against...